title: 20(S)-protopanaxadiol triggers mitochondrial-mediated apoptosis in human lung adenocarcinoma A549 cells via inhibiting the PI3K/Akt signaling pathway.
abstract: 20(S)-Protopanaxadiol (PPD), an aglycone saponin ginsenoside isolated from Panax quinquefolium L, has been shown to inhibit the growth and proliferation in several cancer lines. However, the underlying molecular mechanisms remain poorly understood. In this study, we investigated the apoptosis-induced effects and the mechanism of 20(S)-PPD on human lung adenocarcinoma A549 cells. 20(S)-PPD showed a potent antiproliferative activity against A549 cells by triggering apoptosis. 20(S)-PPD-induced apoptosis was characterized by a dose-dependent loss of the mitochondrial membrane, release of cytochrome c, second mitochondria-derived activator of caspase (Smac) and apoptosis-inducing factor (AIF), activation of caspase-9/-3, and cleavage of poly (ADP-ribose) polymerase (PARP). Caspase-dependence was indicated by the ability of the pan-caspase inhibitor z-VAD-fmk to attenuate 20(S)-PPD-induced apoptosis. After treatment with 20(S)-PPD, the proportion of A549 cells at the G0/G1 phase increased, while cells at the S and G2/M phases decreased. Furthermore, 20(S)-PPD also triggered down-regulation of phosphorylated Akt (Ser473/Thr308) and glycogen synthase kinase 3β (GSK 3β). Knockdown of GSK 3β with siRNA promoted the apoptotic effects of 20(S)-PPD. These results revealed an unexpected mechanism of action for this unique ginsenoside: triggering a mitochondrial-mediated, caspase-dependent apoptosis via down-regulation of the PI3K/Akt signaling pathway in A549 cells. Our findings encourage further studies of 20(S)-PPD as a promising chemopreventive agent against lung cancer.
authors.affiliation: Department of Bioengineering, College of Chemistry, Chemical Engineering and Bioengineering, Donghua University, Shanghai 201620, China.
authors.forename: Yun-Long
authors.initials: YL
authors.lastname: Zhang
authors.forename: Rui
authors.initials: R
authors.lastname: Zhang
authors.forename: Hua-Li
authors.initials: HL
authors.lastname: Xu
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Yu
authors.forename: Shao-Chun
authors.initials: SC
authors.lastname: Qu
authors.forename: Da-Yuan
authors.initials: DY
authors.lastname: Sui
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000517:prevention & control; D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics*; D020169:Caspases / Q000378:metabolism / Q000502:physiology; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology* / Q000517:prevention & control; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D051058:Oncogene Protein v-akt / Q000502:physiology*; D005894:Panax; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology*; D008517:Phytotherapy; D012502:Sapogenins / Q000494:pharmacology* / Q000627:therapeutic use; D015398:Signal Transduction / Q000235:genetics* / Q000502:physiology*; D014407:Tumor Cells, Cultured
chemical_list: D012502:Sapogenins; D019869:Phosphatidylinositol 3-Kinases; D051058:Oncogene Protein v-akt; D020169:Caspases; C062916:protopanaxadiol